Fig. 2

Significant improvements in patient reported outcome scores assessing general, mental and asthmatic health are seen in both ^InitialTPS ≤ 4 and ^InitialTPS ≥ 5 groups after 6 months of dupilumab. Box plots indicating median of Patient Health Questionnaire 2 (PHQ-2) (y-axis = score 0–6) (a), European Quality of Life Five Dimension 3 Level (EQ5D-3L) (y-axis = score 0–15) (b), Asthma Control Test (ACT) (y-axis = score 0–25) (c) and Mini Asthma Quality of Life Questionnaire (Mini-AQLQ) (y-axis = score 0–7) (d) scores at baseline and after 6 months of dupilumab therapy (x-axes). Thick lines within the box plots indicate the median, the edges indicate the lower and upper quartiles and the whiskers indicate variability outside the upper and lower quartiles. Single dots represent outliers. Significant differences are indicated by stars (*: P ≤ 0.05, **: P ≤ 0.01, ***: P ≤ 0.001)